DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Hims & Hers offers compounded semaglutide via telehealth, often at a lower monthly cost than brand-name Wegovy.
A discontinued shortcut now overtaken by FDA-approved options
Hims & Hers compounded semaglutide gave many people their first affordable, convenient access to a GLP-1 drug during the national shortage. But it was never FDA-approved, the semaglutide shortage was declared resolved in February 2025, and Hims's March 2026 settlement with Novo Nordisk is winding the program down for new patients. If you're starting today, the relevant question is no longer "is compounded worth it" but "which FDA-approved GLP-1 should I use" — and Hims now offers branded Wegovy and Zepbound through the same platform. As with any prescription weight-loss drug, the right choice depends on your health history and should be made with a clinician.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Hims & Hers (NYSE: HIMS) is a direct-to-consumer telehealth company that sells men's health, mental health, dermatology, and weight-loss care entirely online. Its weight-loss program is not a drug; it is a subscription service that bundles three things: an asynchronous medical consultation, ongoing provider messaging, and home-delivered medication dispensed through affiliated or partner pharmacies.
The flow is straightforward. You complete an online intake questionnaire covering your weight, height, BMI, medical history, and goals; you may submit photos or lab values. A licensed clinician — often through asynchronous review rather than a live video visit — evaluates whether you qualify and, if so, writes a prescription. Medication then ships monthly. There is no in-person exam, no required bloodwork in most cases, and no relationship with a local pharmacy. For people without easy access to an obesity-medicine clinic, that convenience is the entire value proposition.
What Hims dispenses has changed dramatically. From 2024 through early 2025, the centerpiece was compounded semaglutide — a pharmacy-made copy of the active ingredient in Wegovy and Ozempic, sold at a steep discount. That product was only legally permissible because the FDA had listed semaglutide as being in shortage, which temporarily allows compounding pharmacies to make copies of an otherwise patent-protected drug. When the shortage ended, the legal foundation for that product collapsed.
As of mid-2026, the program spans several distinct tiers, and they are not equivalent in evidence, safety, or legality:
A critical timing note: in early 2026 Hims settled litigation with Novo Nordisk and announced it was exiting compounded GLP-1 sales to become a distributor of brand-name product. Compounded GLP-1 offerings that appear in older reviews and screenshots have therefore been wound down. The branded products are the same medications you would get at any pharmacy. The compounded products — where almost all of the controversy and the real risk lived — are now largely gone from the legitimate offering.
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that slows gastric emptying, blunts appetite signaling in the brain, and enhances glucose-dependent insulin secretion. The net effect for most people is reduced hunger, earlier satiety, and lower calorie intake (NIH).
The efficacy of *FDA-approved injectable* semaglutide at the obesity dose (2.4 mg weekly, branded Wegovy) is well established. In the pivotal STEP 1 trial, adults with overweight or obesity but without diabetes lost a mean of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg plus lifestyle intervention, versus 2.4% on placebo; 86% reached at least 5% weight loss (Wilding et al., NEJM 2021; PMID 33567185). For context, tirzepatide (Zepbound) reached up to 22.5% at its highest dose in SURMOUNT-1 (Jastreboff et al., NEJM 2022), making it the more potent option.
The critical caveat for Hims customers: these numbers come from a *specific molecule at a specific dose in a specific formulation* manufactured under FDA oversight. A compounded copy — particularly an oral one, or one made with a different chemical salt — has no clinical trial data of its own. There is no published evidence that any compounded oral semaglutide product achieves the STEP 1 results, and the brand-name oral semaglutide that does have trial data (Rybelsus, and the higher-dose oral programs studied in the OASIS trials) is a different, patented product Hims does not sell at those validated doses.
This is the story most reviews bury, and it is the most important thing to understand.
Compounding pharmacies are normally barred from mass-producing copies of FDA-approved, patented drugs. A narrow exception exists when the FDA declares the brand drug in shortage. Semaglutide was on that shortage list, which is what let Hims and similar telehealth firms sell cheap copies legally.
On February 21, 2025, the FDA declared the semaglutide shortage resolved (FDA). That announcement set enforcement deadlines: the FDA said it would not act against smaller 503A compounding pharmacies until April 22, 2025, and against larger 503B outsourcing facilities until May 22, 2025 (FDA). Hims's stock fell about 26% the day of the news (CNBC). Compounders, through the Outsourcing Facilities Association, sued the FDA to challenge the determination, but courts denied their requests for injunctions and the enforcement deadlines held — the shortage exception was effectively gone.
The fallout escalated through 2025 and 2026:
The takeaway: the cheap compounded semaglutide that defined Hims's weight-loss business never rested on a durable legal foundation, and after the shortage resolution, the terminated Novo partnership, and the 2026 settlement it has been largely dismantled rather than expanded.
Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality (FDA). That disclaimer is not boilerplate; the FDA has documented concrete harms:
For an oral compounded pill specifically, there is an added pharmacologic problem: semaglutide is a peptide that is poorly absorbed by mouth. Brand-name oral semaglutide (Rybelsus) only works because it is co-formulated with a specialized absorption enhancer (SNAC) and taken under strict fasting conditions. A compounded oral pill without validated formulation and bioavailability testing may simply not deliver a reliable, effective dose — a different but real risk from the overdose problem with injectables.
GLP-1s as a class also carry genuine warnings that apply regardless of source: a boxed warning for thyroid C-cell tumors (based on rodent data; contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2), plus risks of pancreatitis, gallbladder disease, kidney injury from dehydration, and reports of ileus. Common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation (FDA Wegovy label).
It may be reasonable for:
It is a poor fit — or should be approached with real caution — for:
Headline prices are low but typically come with prepayment commitments: the cheapest per-month numbers usually require paying several months upfront. Hims has marketed oral kits at low monthly rates; its compounded GLP-1 injections were reported near $199/month before being wound down; and brand Wegovy was bundled at $599/month during the Novo Nordisk collaboration (Hims; PR Newswire).
On value, the honest assessment is mixed. Brand Wegovy bundled at ~$599/month is in the same range as — or above — manufacturer cash-pay programs. Novo's own NovoCare pharmacy launched direct Wegovy self-pay at $499/month in March 2025 and has since lowered it (to $349/month for existing self-pay patients as of November 2025, with introductory offers as low as $199/month for new patients), so Hims is not a clear savings winner on brand product (PR Newswire). The oral kits are inexpensive but use older generic drugs with far more modest weight-loss effects than GLP-1s. The compounded GLP-1s once looked like the best "deal" on price — and that is precisely where the regulatory and safety discount was hiding. Cheap is not the same as good value when the product may be unapproved, legally exposed, or formulated in ways that haven't been tested.
Hims & Hers Weight Loss is a legitimate, convenient telehealth on-ramp to weight-loss medication — but the product that made it famous and cheap, compounded semaglutide, has been gutted by the end of the FDA shortage, a terminated Novo Nordisk partnership, a 2026 lawsuit and settlement, and active regulatory pressure. The brand-name GLP-1 path is real but not a bargain; the oral generic kits are affordable but modest; and the compounded GLP-1 offerings that once anchored the business carried documented safety concerns and shaky legal standing before being wound down. If you want the roughly 15%-of-body-weight outcomes seen in trials, that evidence belongs to FDA-approved semaglutide 2.4 mg — not to a compounded copy. The most defensible use of Hims here is as a convenient way to access *approved* medication with provider oversight, while treating any "compounded" GLP-1 upsell as a red flag to discuss with an independent clinician first. As always, decisions about prescription weight-loss medication should be made with a qualified healthcare provider who knows your full medical history.
Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a gut hormone released after eating. It slows stomach emptying, signals fullness to the brain's appetite centers, and reduces hunger and food "noise," so people tend to eat less. It also stimulates insulin secretion and helps with blood-sugar control. "Compounded" semaglutide is the same molecule custom-mixed by a pharmacy rather than mass-manufactured and FDA-approved like Wegovy or Ozempic. Hims sold it (typically as a self-injected liquid drawn from a multi-dose vial, and later an oral form) under the temporary legal allowance that existed only while branded semaglutide was officially in shortage.
Active ingredient: Compounded Semaglutide
The efficacy data comes from branded semaglutide, since compounded copies are not separately tested in clinical trials. In the pivotal STEP 1 trial (Wilding et al., NEJM 2021; 1,961 adults), once-weekly injectable semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo, and 86.4% of treated participants lost at least 5% of body weight. The newer oral semaglutide 25 mg (OASIS 4 trial, 64 weeks) showed a mean loss of about 13.6% when counting all randomized participants regardless of whether they stopped treatment, and roughly 16.6% among those who stayed on the drug, versus about 2.4-2.7% with placebo. Compounded products that genuinely contain correctly dosed, properly sourced semaglutide would be expected to perform comparably because it is the same molecule — but their purity, potency, and consistency are not FDA-verified, so individual results and safety can vary.
A realistic timeline of what Hims & Hers Weight Loss users typically experience. Individual results vary; this is educational, not medical advice.
You complete a 100% online medical intake covering health history, current meds, and weight goals. A licensed provider reviews it asynchronously (often within ~24 hours, usually no live video) and, if you qualify, prescribes compounded semaglutide. Discreet packaging with prefilled syringes or a vial plus injection supplies typically arrives in about 3-5 business days. No labs or in-person visit are required to start.
You self-inject once weekly, almost always beginning at a low 0.25 mg starting dose. This first month is intentionally about tolerance, not weight loss; appetite may dip modestly but meaningful scale changes are not expected yet. Mild GI effects (nausea, fullness, constipation) can appear within 1-3 days of an injection. Hims provides unlimited messaging with providers for questions, though there is no scheduled coaching or set check-in cadence.
Your provider steps the dose up roughly every ~4 weeks (commonly toward 0.5, then 1.0, then 1.7 mg, up to a 2.4 mg max), personalized to how you respond. Nausea and other GI side effects tend to flare for a few days after each increase and then settle; in branded semaglutide trials nausea was the most common side effect (~44% at the top dose). If side effects are significant, the provider can slow titration. Appetite suppression usually becomes more noticeable and early weight loss often begins in this window.
Most people reach a maintenance dose and see their fastest rate of weight loss here. In the branded STEP-1 trial, participants lost roughly ~2% of body weight per month over the first six months. GI side effects generally ease substantially after ~4-8 weeks at a steady dose. Compounded semaglutide itself has not been studied in these large trials, so trial figures are a reference point, not a promise; individual results vary widely.
Weight loss typically slows to roughly ~1% per month and then plateaus, often around months 12-16, by which point many have reached most of their expected loss. In the 68-week branded STEP-1 trial, average total loss was about 14.9% (placebo ~2.4%), with substantial person-to-person variation. Maintenance usually means continuing the weekly injection long-term; ongoing prescription and refills depend on continued provider review.
GLP-1 effects depend on continued use. Trial extension data show that appetite and a portion of lost weight tend to return after stopping semaglutide, so this is generally a long-term treatment rather than a short course. Any decision to pause, lower, or stop should go through your provider, and persistent or severe symptoms (intractable vomiting, severe abdominal pain) warrant prompt medical attention.
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate, worst when the dose increases, and often easing over time. Less common but serious risks include pancreatitis, gallstones, kidney injury from dehydration, low blood sugar (especially when combined with diabetes medicines), and a boxed warning for thyroid C-cell tumors based on rodent studies. A distinct risk specific to compounded multi-dose vials: the FDA has logged adverse-event reports — more than 500 for compounded semaglutide as of 2025 — tied largely to self-dosing errors, including cases where patients drew 5 to 20 times the intended dose by confusing milligrams, milliliters, and "units," with some events requiring hospitalization. Always confirm the exact dose and units with your prescriber before injecting, and seek medical care if you suspect an overdose.
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Starts at $199/mo from Hims & Hers.
As of 2026, the compounded semaglutide that made Hims popular ran roughly $150-$250 per month, with promotional first-month or longer-plan offers sometimes advertised lower. With the program winding down, new Hims patients are generally directed to FDA-approved options: branded injectable Wegovy and the oral Wegovy pill have been advertised on the platform in roughly the $249-$299/month range and Zepbound somewhat higher (around $399/month), with some lower-cost subscription plans advertised from about $149/month. Crucially, these are cash/subscription prices; with commercial insurance plus a manufacturer savings card, branded Wegovy can drop to as little as $0-$25/month for eligible patients — often making an approved drug cheaper than people expect. Prices change frequently and vary by plan and eligibility; confirm current figures directly with Hims and check your insurance coverage.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
Compounded semaglutide delivered the same active molecule as Wegovy at a fraction of the price, and many people lost meaningful weight on it. But it skipped FDA review, was tied to more than 500 FDA adverse-event reports driven largely by self-dosing errors, and is now being phased out for new Hims patients after the 2026 Novo Nordisk settlement. New patients should plan on FDA-approved branded GLP-1s, ideally with a clinician's oversight. Discuss your options with a healthcare provider before starting, switching, or stopping any GLP-1 medication.
No. Compounded semaglutide is not FDA-approved, meaning the FDA does not review it for safety, effectiveness, purity, or potency before it is sold. Only branded products like Wegovy and Ozempic carry FDA approval; compounded versions were permitted only as a temporary measure during the official semaglutide shortage.
Generally no for new patients. After the FDA declared the semaglutide shortage resolved in February 2025 and Hims reached a March 2026 settlement and partnership with Novo Nordisk, Hims is winding down routine compounded semaglutide and directing new patients to FDA-approved branded Wegovy, oral Wegovy, or Zepbound. Compounding is now reserved for limited medically necessary cases, and existing patients should ask Hims about their specific situation.
If it contains correctly dosed, properly sourced semaglutide, it should work similarly because it is the same molecule — branded semaglutide produced about 15% average weight loss in the STEP 1 trial. The catch is that compounded products are not FDA-tested, so their actual potency, purity, and consistency are not guaranteed, and results can vary between products and pharmacies.
In June 2025, Novo Nordisk terminated its short-lived collaboration with Hims, alleging that Hims engaged in illegal mass compounding disguised as 'personalization' and disseminated deceptive marketing, and raising concerns that knockoff semaglutide ingredients were made by foreign suppliers whose manufacturing the FDA had never authorized. The companies later reached a settlement and a new partnership in March 2026, under which Hims offers Novo's branded products and stops marketing compounded GLP-1s except where medically necessary.
The compounded program historically ran about $150-$250 per month with occasional promotional pricing. New patients are now steered to FDA-approved options, with branded Wegovy and oral Wegovy advertised roughly in the $249-$299 range and Zepbound somewhat higher, and some lower-cost subscription plans from about $149/month. Insurance plus a manufacturer savings card can bring branded Wegovy to as little as $0-$25/month for eligible patients, so check your coverage; prices change frequently.
The most common are gastrointestinal — nausea, diarrhea, vomiting, and constipation — usually mild and improving over time. Serious but rarer risks include pancreatitis, gallstones, kidney problems from dehydration, and a boxed warning for thyroid tumors seen in rodents. Compounded multi-dose vials also carry a documented risk of dangerous self-dosing errors, so report severe or persistent symptoms to a clinician promptly.
Compounded semaglutide usually came in a multi-dose vial requiring you to draw your own dose, so the biggest danger is measuring incorrectly. Always confirm the exact dose in milligrams and the matching syringe volume with your prescriber, never assume 'units' equals milliliters, and follow the once-weekly escalating schedule precisely. The FDA linked hundreds of overdose reports to vial measurement errors, some requiring hospitalization, so check with the prescriber whenever you are unsure.
For most new patients, an FDA-approved branded GLP-1 is now the safer and more sustainable choice, since it is quality-verified and the compounded supply is being phased out. This is a medical decision: talk to your prescriber about transitioning to Wegovy or another approved drug, and check whether insurance and manufacturer savings cards make the branded version affordable for you.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Hims & Hers Weight Loss — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
Many brand-name drugs have a manufacturer copay-savings program on the drug’s official site. Check the maker’s website for a current savings card (commercial insurance usually required; government insurance excluded).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.